Anemia and iron deficiency in heart failure

Heart Failure Clinics

Volumn 10, Issue 2, 2014, Pages 281-294

  Arora, Natasha P ^a   Ghali, Jalal K ^b  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Erythropoiesis stimulating agents; Heart failure; Iron deficiency; Iron therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; INTERLEUKIN 1; INTERLEUKIN 6; IRON; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; COMORBIDITY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FUNCTIONAL STATUS; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANEMIA, IRON-DEFICIENCY; COMPLICATION;

ANEMIA, IRON-DEFICIENCY; HEART FAILURE; HUMANS;

EID: 84896377229     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.11.002     Document Type: Review

References (82)

1. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005, 149(3):391-401.
2. Ghali J.K. Anemia and heart failure. Curr Opin Cardiol 2009, 24(2):172-178.
3. Groenveld H.F., Januzzi J.L., Damman K., et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. JAm Coll Cardiol 2008, 52(10):818-827.
4. Arora N.P., Ghali J.K. Iron deficiency anemia in heart failure. Heart Fail Rev 2013, 18(4):485-501.
5. Duffy T.P. Microcytic and hypochromic anemias. Cecil textbook of medicine 2004, 1003-1008. Saunders, Philadelphia. L. Goldman, D. Ausiello (Eds.).
6. Caira C., Ansalone G., Mancone M., et al. Heart failure and iron deficiency anemia in Italy: results from CARMES-1 registry. Future Cardiol 2013, 9(3):437-444.
7. Beutler E., Waalen J. The definition of anemia; what is the lower limit of normal of the blood hemoglobin concentration?. Blood 2006, 107:1747-1750.
8. Zuccala G., Marzetti E., Cesari M., et al. Correlates of cognitive impairment among patients with heart failure: results of a multicenter survey. Am J Med 2005, 118(5):496-502.
9. Salisbury A.C., Kosiborod M. Outcomes associated with anemia in patients with heart failure. Heart Fail Clin 2010, 6(3):359-372.
10. Horwich T.B., Fonarow G.C., Hamilton M.A., et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. JAm Coll Cardiol 2002, 39(11):1780-1786.
11. Kalra P.R., Bolger A.P., Francis D.P., et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003, 91(7):888-891.
12. Adams K.F., Pina I.L., Ghali J.K., et al. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J 2009, 158(6):965-971.
13. de Silva R., Rigby A.S., Witte K.K., et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol 2006, 98(3):391-398.
14. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. JAm Coll Cardiol 2006, 48(12):2485-2489.
15. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010, 31(15):1872-1880.
16. Klip I.T., Comin-Colet J., Voors A.A., et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013, 165(4):575-582.e3.
17. Okonko D.O., Mandal A.K., Missouris C.G., et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. JAm Coll Cardiol 2011, 58(12):1241-1251.
18. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. JCard Fail 2011, 17(11):899-906.
19. Comin-Colet J., Lainscak M., Dickstein K., et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013, 34(1):30-38.
20. Jankowska E.A., Ponikowski P. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 2010, 6(3):295-304.
21. Le Jemtel T.H., Arain S. Mediators of anemia in chronic heart failure. Heart Fail Clin 2010, 6(3):289-293.
22. Weiss G., Goodnough L.T. Anemia of chronic disease. NEngl J Med 2005, 352(10):1011-1023.
23. Freudenthaler S.M., Schreeb K., Korner T., et al. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999, 29(10):816-823.
24. Opasich C., Cazzola M., Scelsi L., et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005, 26(21):2232-2237.
25. Belonje A.M., Voors A.A., van Gilst W.H., et al. Erythropoietin in chronic heart failure. Congest Heart Fail 2007, 13(5):289-292.
26. Belonje A.M., Voors A.A., van der Meer P., et al. Endogenous erythropoietin and outcome in heart failure. Circulation 2010, 121(2):245-251.
27. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009, 1790(7):682-693.
28. Handelman G.J., Levin N.W. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008, 13(4):393-404.
29. Naito Y., Tsujino T., Fujimori Y., et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. JHypertens 2011, 29(4):741-748.
30. Merle U., Fein E., Gehrke S.G., et al. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 2007, 148(6):2663-2668.
31. Matsumoto M., Tsujino T., Lee-Kawabata M., et al. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ J 2010, 74(2):301-306.
32. Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002, 99(7):4596-4601.
33. Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011, 62:347-360.
34. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
35. van der Putten K., Jie K.E., van den Broek D., et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010, 12(9):943-950.
36. Jankowska E.A., Malyszko J., Ardehali H., et al. Iron status in patients with chronic heart failure. Eur Heart J 2013, 34(11):827-834.
37. Haas J.D., Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. JNutr 2001, 131(2S-2):676S-688S. [discussion: 688S-90S].
38. Cairo G., Bernuzzi F., Recalcati S. Aprecious metal: iron, an essential nutrient for all cells. Genes Nutr 2006, 1(1):25-39.
39. Anderson G.J., Vulpe C.D. Mammalian iron transport. Cell Mol Life Sci 2009, 66(20):3241-3261.
40. Andrews N.C. Disorders of iron metabolism. NEngl J Med 1999, 341(26):1986-1995.
41. Sutak R., Lesuisse E., Tachezy J., et al. Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol 2008, 16(6):261-268.
42. Wilson M.T., Reeder B.J. Oxygen-binding haem proteins. Exp Physiol 2008, 93(1):128-132.
43. Gomollon F., Gisbert J.P. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009, 15(37):4659-4665.
44. Zimmermann M.B., Hurrell R.F. Nutritional iron deficiency. Lancet 2007, 370(9586):511-520.
45. Anker S.D., Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002, 85(1):51-66.
46. Dong F., Zhang X., Culver B., et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005, 109(3):277-286.
47. Katz S.D., Zheng H. Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. JNucl Cardiol 2002, 9(2):215-225.
48. Brownlie T., Utermohlen V., Hinton P.S., et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004, 79(3):437-443.
49. van Veldhuisen D.J., Anker S.D., Ponikowski P., et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011, 8(9):485-493.
50. Maeder M.T., Khammy O., dos Remedios C., et al. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. JAm Coll Cardiol 2011, 58(5):474-480.
51. Cunietti E., Chiari M.M., Monti M., et al. Distortion of iron status indices by acute inflammation in older hospitalized patients. Arch Gerontol Geriatr 2004, 39(1):35-42.
52. Means R.T., Allen J., Sears D.A., et al. Serum soluble transferrin receptor and the prediction of marrow aspirate iron results in a heterogeneous group of patients. Clin Lab Haematol 1999, 21(3):161-167.
53. Cook J.D., Skikne B.S., Baynes R.D. Serum transferrin receptor. Annu Rev Med 1993, 44:63-74.
54. Beguin Y., Clemons G.K., Pootrakul P., et al. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993, 81(4):1067-1076.
55. Punnonen K., Irjala K., Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997, 89(3):1052-1057.
56. Thomas C., Kirschbaum A., Boehm D., et al. The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy. Med Oncol 2006, 23(1):23-36.
57. Thomas C., Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002, 48(7):1066-1076.
58. Leszek P., Sochanowicz B., Szperl M., et al. Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol 2012, 159(1):47-52.
59. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. JAm Coll Cardiol 2001, 37(7):1775-1780.
60. Mancini D.M., Katz S.D., Lang C.C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107(2):294-299.
61. Ponikowski P., Anker S.D., Szachniewicz J., et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. JAm Coll Cardiol 2007, 49(7):753-762.
62. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007, 28(18):2208-2216.
63. Ghali J.K., Anand I.S., Abraham W.T., et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117(4):526-535.
64. Parissis J.T., Kourea K., Panou F., et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008, 155(4):751.e1-751.e7.
65. Kourea K., Parissis J.T., Farmakis D., et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008, 15(3):365-369.
66. Parissis J.T., Kourea K., Andreadou I., et al. Effects of darbepoetin alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2009, 103(8):1134-1138.
67. Cosyns B., Velez-Roa S., Drrogmans S., et al. Effects of erythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. Int J Cardiol 2010, 138(3):306-307.
68. Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. NEngl J Med 2013, 368(13):1210-1219.
69. Klapholz M., Abraham W.T., Ghali J.K., et al. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 2009, 11:1071-1077.
70. Kotecha D., Ngo K., Walters J.A., et al. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 2011, 161(5):822-831.e2.
71. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. JAm Coll Cardiol 2006, 48(6):1225-1227.
72. Toblli J.E., Lombrana A., Duarte P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. JAm Coll Cardiol 2007, 50(17):1657-1665.
73. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. JAm Coll Cardiol 2008, 51(2):103-112.
74. Usmanov R.I., Zueva E.B., Silverberg D.S., et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. JNephrol 2008, 21(2):236-242.
75. Drakos S.G., Anastasiou-Nana M.I., Malliaras K.G., et al. Anemia in chronic heart failure. Congest Heart Fail 2009, 15(2):87-92.
76. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. NEngl J Med 2009, 361(25):2436-2448.
77. Beck-da-Silva L., Piardi D., Soder S., et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013, 168(4):3439-3442. pii:S0167-5273(13)00848-6. 10.1016/j.ijcard.2013.04.181.
78. Kapoor M., Schleinitz M.D., Gemignani A., et al. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord Drug Targets 2013, 13(1):35-44.
79. Besarab A., Bolton W.K., Browne J.K., et al. The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. NEngl J Med 1998, 339:584-590.
80. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. NEngl J Med 2006, 355:2071-2084.
81. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. NEngl J Med 2006, 355:2085-2098.
82. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. Atrial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. NEngl J Med 2006, 355:2085-2098.